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A Novel Hematopoietic Progenitor Cell (HPC)
Mobilization Regimen, Utilizing Bortezomib and
Filgrastim (G-CSF), for Patients Undergoing Autologous
HPC Transplant (AHPCT) for Multiple Myeloma (MM) and
Non-Hodgkin's Lymphoma (NHL)
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Adequate HPC collection is critical for patients under-
going AHPCT. HPC mobilization is usually done with G-CSF,
which affects the stromal derived factor-1a interaction with
HPC. Other adhesion molecules also play a role in HPC
mobilization e.g. very late antigen-4 (VLA-4) expressed on
HPCs, and its ligand, vascular cell adhesion molecule-1,
expressed on the bone marrow microenvironment. Borte-
zomib, a proteasome inhibitor, has been shown to down
regulate VLA-4. In this study, bortezomib was used with
G-CSF to mobilize and collect HPC for AHPCT. Sixteen
patients (11 males), aged 42 e 70 years, with MM (n¼9) or
NHL (n¼7,) undergoing AHCPT for the ﬁrst time, were
enrolled after obtaining consent. Patients with >grade II
neuropathy or platelet count <100K/ml were excluded.
Bortezomib was administered on days -11 and -8 at a dose of
1.3mg/m2 iv, followed by G-CSF 10mg/kg sc, on days -4 to -1
prior to HPC collection (day 0). Results were compared with
matched patients with MM or NHL undergoing AHPCT at our
Institution. All patients had CD34+ cell enumeration from the
peripheral blood on the day of collection, and followed
a published Institutional algorithm regarding the use of
plerixafor. If the CD34+ cell count was adequate, patients
underwent a high volume HPC collection, if the CD34+ count
was <5/ml, then they received plerixafor. In this study, one
patient (6%) had CD34+ cell count of 3.9/ml on day 0 and
received plerixafor, as compared to 33% of matched historical
controls. Botezomibr was well tolerated and all patients had
adequate HPC collections with no mobilization failures. 10
patients completed HPC collection in one day and 7 in two
days. All patients had timely neutrophil and platelet
engraftment post AHPCT. Bortezomib + G-CSF is an effective
HPC mobilizing regimen worth investigating in subsequent
studies. Bortezomib also has known anti MM and NHL
effects.127
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Background: In a recent phase IIa open-label, randomized,
cross-over design study, we evaluated the pharmacokinetics
of Propylene Glycol-Free Melphalan (PG-free Mel) HCL and
Alkeran in multiple myeloma patients undergoing trans-
plantation. In this study, we have shown through statistical
tests of the geometric means of AUC that PG-free Mel was
bioequivalent to Alkeran, and provided marginally higher
blood drug levels.
Hypothesis: Because this new formulation is associated with
marginally higher blood drug levels and because melphalan
is associated with a linear dose-response curve, we specu-
lated that patients treated on study would have a better
multiple myeloma response compared to matched controls.
Goal: To assess day +100 multiple myeloma responses from
the study patients (N¼24) receiving PG-free Mel condi-
tioning in combination with Alkeran. Responses were
assessed based on International Uniform Response Criteria
for Multiple Myeloma. Comparison was made to a matched
cohort of patients who received conventional melphalan.
Methods: We compared the study patient responses to
matched controls (N¼24) treated exclusively with Alkeran or
generic melphalan conditioning within the same time frame
in a case-control study design. The controls were matched to
study population based on disease stage, age, and pre-
transplant response.
Results: The study population and the control cohort were
well matched in terms of age, gender, disease stage, and pre-
transplant response. However, the study population had
higher-risk cytogenetics (10 vs 3). Overall response (CR,
VGPR, and PR) was higher in the study population (22 vs 19).
While no patient on the study progressed within 100 days of
transplant, 3 patients in the matched cohort progressed
within 100 days. After a median follow up of 650 days in the
study patients and 409 days in the control cohort, 23 patients
on the study and 22 patients in the matched cohort were
reported alive. Seven patients on the study, while 8 patients
in the matched cohort progressed during follow up.
Conclusion: Compared to matched controls, PG-free Mel, as
part of the melphalan conditioning regimen, achieved higher
remission rates and less disease progression at day 100 post
autologous transplant for multiple myeloma.
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Introduction: High dose chemotherapy and autologous
hematopoietic stem cell transplantation (AHSCT) has been
widely used in the treatment of relapsed/refractory patients.
As there are a few randomized studies comparing the
conditioning regimens in AHSCT, we aim to analyze the
transplant outcomes of the patients who has been treated
with BEAM or ICE regimens.
Patients-Method: We included sixty eight Hodgkin/Non
Hodgkin lymphoma patients, who had been transplanted in
our Bone Marrow Transplantation Unit between 2010-2012.
Demographic features of the patients are summarized in
Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193 S179Table 1. Only mantle cell and T cell lymphoma patients were
transplanted in ﬁrst CR otherwise all patients were
transplanted in relapsed/refractory setting. Patients were
grouped according to conditioning regimens.We aimed to
analyze the difference between the groups due to the total
number of febrile neutropenic days and hospitalization .We
also planned to compare the engraftment kinetics and side
effects between the groups.Table 1.
Patient demographics
BEAM(n:42) ICE(n:26)
Diagnosis
Hodgkin/Non Hodgkin lymphoma(n)
17/25 12/14 P:0.364
Median age (range) 43(17-66) 42(20-66) P:0.622
Gender:F/M 26/16 18/8 P: 0.417
Pretransplantation status
CR/PR/Refractory(n)
29/5/8 19/2/5 P:0.623
Pretransplantation RT(n) 9 5 P:0.542Results: The groupswere comparable according to diagnosis,
age, gender, pretransplantation status of disease and pre-
transplantation radiotherapy. We also showed no difference
between the groups according to infused CD344 cells, the
number of febrile neutropenic days,hospitalization and
neutrophile,platelet engraftment kinetics (Table 2). Nausea/
vomitting was slightly higher in the BEAM group but the
rates of mucositis were similar between the groups.Table 2
Transplant outcomes
BEAM ICE
Mean of transplanted CD34+ cells 6.4 3.3 5.7 2.8 P:0.364
Day Number of febrile neutropenia 3(1-12) 4(1-10) P:0.613
Day number of hospitalization 26(9-50) 24(12-67) P:0.846
No of neutrophile engraftment day 12(9-34) 11(8-21) P:0.354
No of platelet engraftment day 12(9-25) 12(8-21) p:0.500Conclusion: BEAM is one of the earliest described and
traditionally accepted conditioning regimens in AHSCT of
Hodgkin/Non Hodgkin lymphoma patients. Attempts of
several groups to change the drugs in BEAM regimens
showed no evidence of more antitumor effect. We showed
comparable transplantation outcomes between ICE and
BEAM regimens.
We conclude that ICE regimen can be preffered as
a conditioning regimen instead of BEAM regimen in selected
patient groups.129
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Peripheral blood has largely replaced bone marrow as the
source of stem cells for autologous transplantation. The
number of cells infused is a key determinant of hematopoi-
etic recovery after transplantation. Peripheral blood stem cell
(PBSC) yield can be affected by several factors such as donor
characteristics, disease status and prior treatment regimens.
We retrospectively analyzed the effect of body mass index
(BMI) on PBSC mobilization in 164 patients with plasma cell
dyscrasias. Patients were segregated based on BMI <25(Group I), 25-30 (Group II) and>30 (Group III). Since G-CSF is
dosed according to the actual body weight, patients with
higher BMI received higher total G-CSF dose (as well as
higher dose per kg ideal body weight) but the median stem
cell yield per kg IBW was similar in the 3 groups. (I¼ 2.2 x
103 cells/Kg, II¼ 2.1 x 103 cells/Kg and III¼ 2.3 x 103 cells/Kg;
P ¼ .76). We also evaluated the effect of BMI on the mobi-
lizing efﬁcacy of plerixafor. In our institution, patients
receive G-CSF at a dose of 10 mg/Kg daily subcutaneous
injections for three consecutive days. Patients with periph-
eral CD34+ cell count less than 10 x 106/L are considered
“poor mobilizers” and plerixafor at a dose of 0.24 mg/Kg SQ
daily is initiated starting on the fourth day for a maximum of
four days or until target number of cells are collected. The
fold increase in the median peripheral blood CD34+ count
after one dose of plerixafor was 8.1 (7.1  57.2/uL), 6.8 (7.2 
49.5/uL) and 3.6 (11  40.3 /uL) in BMI groups I, II and III,
respectively (p¼0.0675). Similarly, the administration of
plerixafor in addition to G-CSF did not give as much beneﬁt
in stem cell yield in higher BMI groups as seen in BMI < 25
group (p¼0.0063 in BMI<25 group and P ¼ .30 in BMI >30).
The reasons for these effects are unclear. Homing of the HPCs
in the adipose tissue (AT) may be a factor in higher BMI
individuals as the adipose tissue has similar biochemical and
molecular microenvironment as the bone marrow. The
pathophysiologic changes associated with obesity may alter
the pharmacokinetics and pharmacodynamics of subcuta-
neously administered drugs leading to their impaired efﬁ-
cacy. We believe these initial observations may have
important implications for clinical practice. Prospective
studies are needed to validate these ﬁndings and explore
whether these effects can be mitigated by intravenous route
of plerixafor administration.130
Safety and Efﬁcacy of Plerixafor (Mozobil) Addition to
Chemotherapy and Growth Factor Stem Cell Mobilization
Regimens in Patients with Low Pre-CD34 Counts
Undergoing Stem Cell Collection Prior to Autologous
Stem Cell Transplantation
Ruthee-Lu Bayer 1, Alla Keyzner 1, Laura Donahue 2,
Claudia Elera 3, Rose Roddy 4. 1 Hematology/Oncology, North
Shore University Hospital, Lake Success, NY; 2Hematology
Oncology, North Shore University Hospital; 3 North Shore
University Hospital, Lake Success, NY; 4 North Shore University
Hospital
Prior to introduction of Plerixafor, CXCR4 receptor antago-
nist, up to 30% of patients in need of autologous stem cell
transplant were unable to collect adequate numbers of
peripheral blood stem cells (PBSCs). Plerixafor is currently
approved for hematopoetic stem cell mobilization and
collection in combination with Filgrastim in patients with
Non-Hodgkin Lymphoma (NHL) and multiple myeloma
(MM) undergoing autologous stem cell transplantation. Due
to high costs associated with use of Plerixafor, the above
combination is usually reserved for patients who are at high
risk of failure or fail previous stem cell mobilization.
We have administed Plerixafor to 13 patients that failed to
achieve adequate peripheral blood pre CD34 counts after
undergoing stem cell mobilization utilizing the combination
of chemotherapy and Pegﬁlgrastim. We retrospectively
reviewed our data to evaluate efﬁcacy and safety of the above
combination.
Thirteen patients (25-69 years) with lymphoma (NHL
n¼ 4 HL n¼ 2) and MM (n¼7) underwent treatment with ICE
based chemotherapy or Cytoxan 3 gm/m2 followed by
